Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer

NCT01004731 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Stage IV Non-Small Cell Lung Cancer

Interventions

DRUG: Cetuximab in combination with Carboplatin/Gemcitabine

Sponsor

University of Alabama at Birmingham

Collaborators

[object Object]